Skip to main content
Premium Trial:

Request an Annual Quote

Reveal Biosciences to Use Affy ISH Tech With Image-Analysis Software

NEW YORK (GenomeWeb) – Reveal Biosciences has signed a deal to use Affymetrix's ViewRNA ISH products with tissue samples to provide RNA in situ hybridization staining, imaging, and quantification services in combination with its ImageDx image-analysis software, the companies announced today.

Specific terms of the deal were not disclosed.

"RNA in situ hybridization is fast becoming the method of choice for researchers wanting to validate established and novel biomarkers for translational and clinical research," Guy Afseth, marketing director for Affy's oncology portfolio, said in a statement.

"Our scientific expertise, combined with high-resolution imaging and our proprietary image analysis software … form a powerful platform for the localization and quantification of mRNA in tissue samples," Reveal Founder and CEO Claire Weston, added in the statement.

ViewRNA combines target-specific probe sets and branched DNA signal amplification for the detection of specific signals. ImageDx is designed to provide quantification data including percentage positivity and staining intensity over whole-slide images or single field or view images.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.